Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esteban Alberto Gonzalez

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Interdisciplinary Sciences, Computational Life Sciences|January 21, 2021
Network Analysis Reveals Proteins Associated with Aortic Dilatation in MucopolysaccharidosesThiago Corrêa, Bruno César Feltes, Esteban Alberto Gonzalez, et al.
Journal of Inherited Metabolic Disease|February 5, 2017
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis IEsteban Alberto Gonzalez, Angela Maria Vicente Tavares, Edina Poletto, et al.
Advances in Experimental Medicine and Biology|July 24, 2023
Genome Editing Tools for Lysosomal Storage DisordersEsteban Alberto Gonzalez, Helena Nader, Marina Siebert, et al.
American Journal of Medical Genetics. Part A|January 12, 2020
Estimated birth prevalence of mucopolysaccharidoses in BrazilAndressa Federhen, Gabriela Pasqualim, Talita Freitas de Freitas, et al.
Progress in Molecular Biology and Translational Science|June 27, 2021
Genome editing in lysosomal disordersLuisa Natalia Pimentel-Vera, Edina Poletto, Esteban Alberto Gonzalez, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|September 20, 2023
Characterization of heart disease in mucopolysaccharidosis type II miceAngela Maria Vicente Tavares, Esteban Alberto Gonzalez, Isabelle Souza Viana, et al.
Life Sciences|January 26, 2018
Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I miceEsteban Alberto Gonzalez, Giselle Renata Martins, Angela Maria Vicente Tavares, et al.
Journal of Inherited Metabolic Disease|November 4, 2020
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodelingEsteban Alberto Gonzalez, Santiago Alonso Tobar Leitão, Douglas Dos Santos Soares, et al.
BMC Cancer|May 28, 2020
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cellsJosé Ignácio Gonzalez Solari, Eduardo Filippi-Chiela, Emily Salles Pilar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 1, 2018
In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 systemRoselena Silvestri Schuh, Édina Poletto, Gabriela Pasqualim, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Interdisciplinary Sciences, Computational Life Sciences|January 21, 2021
Network Analysis Reveals Proteins Associated with Aortic Dilatation in MucopolysaccharidosesThiago Corrêa, Bruno César Feltes, Esteban Alberto Gonzalez, et al.
Journal of Inherited Metabolic Disease|February 5, 2017
Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis IEsteban Alberto Gonzalez, Angela Maria Vicente Tavares, Edina Poletto, et al.
Advances in Experimental Medicine and Biology|July 24, 2023
Genome Editing Tools for Lysosomal Storage DisordersEsteban Alberto Gonzalez, Helena Nader, Marina Siebert, et al.
American Journal of Medical Genetics. Part A|January 12, 2020
Estimated birth prevalence of mucopolysaccharidoses in BrazilAndressa Federhen, Gabriela Pasqualim, Talita Freitas de Freitas, et al.
Progress in Molecular Biology and Translational Science|June 27, 2021
Genome editing in lysosomal disordersLuisa Natalia Pimentel-Vera, Edina Poletto, Esteban Alberto Gonzalez, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|September 20, 2023
Characterization of heart disease in mucopolysaccharidosis type II miceAngela Maria Vicente Tavares, Esteban Alberto Gonzalez, Isabelle Souza Viana, et al.
Life Sciences|January 26, 2018
Cathepsin B inhibition attenuates cardiovascular pathology in mucopolysaccharidosis I miceEsteban Alberto Gonzalez, Giselle Renata Martins, Angela Maria Vicente Tavares, et al.
Journal of Inherited Metabolic Disease|November 4, 2020
Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodelingEsteban Alberto Gonzalez, Santiago Alonso Tobar Leitão, Douglas Dos Santos Soares, et al.
BMC Cancer|May 28, 2020
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cellsJosé Ignácio Gonzalez Solari, Eduardo Filippi-Chiela, Emily Salles Pilar, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 1, 2018
In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 systemRoselena Silvestri Schuh, Édina Poletto, Gabriela Pasqualim, et al.
Pageof 2